Abstracts tagged "Biomarkers"

Abstract Number: 0795 • ACR Convergence 2020
Minimum Clinically Important Improvement in Patients with Rheumatoid Arthritis Associates with Gut Microbiome
Vinod Gupta¹, Kevin Cunningham², Benjamin Hur¹, John Davis¹ and Jaeyun Sung¹, ¹Mayo Clinic, Rochester, MN, ²University of Minnesota, Minneapolis, MN
Background/Purpose: Within the past decade, there have been several major discoveries in cross-sectional gut microbiome studies suggesting that dysbiosis of the gut microbiota is a…
Abstract Number: 1180 • ACR Convergence 2020
External Validation of a Multi-biomarker-Based Cardiovascular Disease Risk Prediction Score for Rheumatoid Arthritis Patients
Jeffrey R Curtis¹, Eric Sasso², Elena Hitraya², Cheryl Chin³, Richard Bamford³, Rotem Ben-Shachar³, Alexander Gutin³, Darl Flake³, Brent Mabey³ and Jerry Lanchbury³, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Myriad Autoimmune, South San Francisco, CA, ³Myriad Genetics, Inc., Salt Lake City, UT
Background/Purpose: A novel score for predicting 3-year risk for CVD events in RA patients combines age, four traditional CVD risk factors (diabetes, hypertension, smoking, history…
Abstract Number: 1277 • ACR Convergence 2020
Low Cost Composite Markers to Differentiate Infection from Disease Activity in a Febrile Patient with Systemic Lupus Erythematosus
Pankti Mehta¹, Komal Singh¹, Amita Aggarwal¹ and Seema Sharma¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) are at an increased risk of infection owing to immunosuppressive therapy along with coexistent immune dysregulation. It is…
Abstract Number: 1730 • ACR Convergence 2020
Comparison of MBDA Score, Patient Global Assessment and Evaluator Global Assessment for Predicting Risk of Radiographic Progression
Leonard Calabrese¹, Michael Weinblatt², Nancy Shadick², Cecilie Hegaard Brahe³, Mikkel Østergaard⁴, Merete Hetland⁵, Megan Horton⁶, Darl Flake⁶ and Eric Sasso⁷, ¹Cleveland Clinic, Cleveland, OH, ²Brigham and Women's Hospital, Boston, MA, ³Center for Rheumatology and Spine diseases, Glostrup, Denmark, ⁴Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ⁵The DANBIO Registry, Rigshospitalet, Glostrup, Denmark, ⁶Myriad Genetics, Inc., Salt Lake City, UT, ⁷Myriad Autoimmune, South San Francisco, CA
Background/Purpose: To compare the abilities of MBDA score, patient global assessment (PGA) and evaluator global assessment (EGA) to assess risk for radiographic progression (RP), and…
Abstract Number: 1822 • ACR Convergence 2020
Serum Proteomics from a Phase III, Randomized, Placebo-Controlled Study of Patients with Active Lupus Nephritis: Correlation with Baseline Disease Characteristics and Response to Therapy
Shiliang Wang¹, Richard Furie², Mary Anne Dooley³, David Wofsy⁴, Tsutomu Takeuchi⁵, Ana Malvar⁶, Andrea Doria⁷, Juanita Romero-Díaz⁸, Tak Mao Chan⁹, Gerald Appel¹⁰, David Jayne¹¹, Sarah Hu¹², Sheng Gao¹³ and Michael Maldonado¹², ¹Bristol-Myers Squibb Company (at the time of analysis), Princeton, NJ, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³University of North Carolina, Chapel Hill, NC, ⁴University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ⁶Organizacion Medica de Investigacion, Buenos Aires, Argentina, ⁷University of Padua, Padua, Italy, ⁸Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁹University of Hong Kong, Hong Kong, Hong Kong, ¹⁰Columbia University Medical Center, New York, NY, ¹¹Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ¹²Bristol-Myers Squibb Company, Princeton, NJ, ¹³Bristol-Myers Squibb Company (at the time of analysis), Princeton, NY
Background/Purpose: The ALLURE study compared efficacy and safety of abatacept (ABA) vs placebo (PBO) on background MMF and CS for the treatment of active proliferative…
Abstract Number: 0341 • ACR Convergence 2020
Metabolomics Profiling of Human Serum for Discovering Biomarkers to Diagnose Psoriatic Arthritis and Ankylosing Spondylitis with High Specificity
Wei Han¹, Xiaohang Wang¹, Liang Li¹, Stephanie Wichuk², Edna Hutchings³, Rana Dadashova³, Joel Paschke³ and Walter Maksymowych², ¹Department of Chemistry, University of Alberta, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: In this work, we applied a high-performance chemical isotope labeling (CIL) LC-MS platform to search for biomarker candidates of PsA and AS in human…
Abstract Number: 0719 • ACR Convergence 2020
Anti-adalimumab Antibodies Detection Using a Novel Peptide-based Assay in a Cohort of Pediatric Patients with Chronic Rheumatic Disorders: A Pilot Study
Edoardo Marrani¹, Hendrik Rusche², Francesco Terzani³, Elisa Peroni⁴, Feliciana Real-Fernandez⁵, Olivier Monasson⁴, Roberta Ponti⁶, Gabriele Simonini⁷, Anna Maria Papini³ and Paolo Rovero⁵, ¹University of Florence, Firenze, Italy, ²Peptlab@CY and Laboratory of Chemical Biology, Cergy-Paris University, Cergy-Pontoise,, France, ³PeptLab, Dep. Chemistry, University of Florence, Sesto FIorentino, Italy, ⁴Peptlab@CY and Laboratory of Chemical Biology, Cergy-Paris University, cergy-pontoise, France, ⁵PeptLab, Dep. NEUROFARBA, University of Florence, Firenze, Italy, ⁶Pediatric Department, University of Udine, udine, Italy, ⁷Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy
Background/Purpose: Immunogenicity and development of anti-drug antibodies have been associated with treatment failure and adverse events during biologic treatment. Anti-drug antibodies (ADAs) have been reported…
Abstract Number: 0847 • ACR Convergence 2020
Impact of Hydroxychloroquine Treatment on Immunologic Markers in SLE Depends on Ethnicity
Laurence Magder¹, Daniel Goldman² and Michelle Petri², ¹University of Maryland, Baltimore, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: SLE patients with certain immunological markers (i.e., anti-DNA, low complement) are at higher risk of lupus nephritis and those with antiphospholipid antibodies are at…
Abstract Number: 1185 • ACR Convergence 2020
Performance of the MBDA-based CVD Risk Score in RA Patient Groups of Clinical Interest
Jeffrey R Curtis¹, Fenglong Xie², Cynthia Crowson³, Eric Sasso⁴, Elena Hitraya⁴, Cheryl Chin⁵, Richard Bamford⁵, Rotem Ben-Shachar⁵, Alexander Gutin⁵, Darl Flake⁵, Brent Mabey⁵ and Jerry Lanchbury⁵, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ⁴Myriad Autoimmune, South San Francisco, CA, ⁵Myriad Genetics, Inc., Salt Lake City, UT
Background/Purpose: A novel risk prediction score combines serum biomarkers from the multi-biomarker disease activity (MBDA) test with clinical information to predict 3-year risk for a…
Abstract Number: 1297 • ACR Convergence 2020
Lupus Antibodies in Relation to Malignancy
Sarah Huse¹, Jim Oates², Gary Gilkeson³ and Diane Kamen¹, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, SC, Charleston, SC, ³Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) a chronic inflammatory autoimmune disease that has the potential to affect every organ system. Studies have shown increased risk of…
Abstract Number: 1747 • ACR Convergence 2020
Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Multi-center, Randomized, Double-blind, Placebo-controlled Trial (PreCePRA)
Juergen Rech¹, Hannah Schenker², Koray Tascilar¹, Melanie Hagen², Arnd Kleyer¹, David Simon¹, Larissa Valor Mendez², Verena Schoenau³, Jutta Prade⁴, Marina Sergeeva⁴, Mageshvar Sulvakumar⁵, Sandra Strobelt⁴, Laura Konerth⁴, Frank Behrens⁶, Christoph Baerwald⁷, Stephanie Finzel⁸, Reinhard Voll⁹, Axel Hueber¹⁰, Julie Roesch¹¹, Eugen Feist¹², José A. P. da Silva¹³, Arnd Doerfler¹¹, Nemanja Damjanov¹⁴, Andreas Hess¹⁵ and Georg Schett¹⁶, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, ³Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, ⁴Institute for Experimental Pharmacology, Erlangen, Germany, ⁵Insitute for Experimental Pharmacology , Fau Erlangen-Nürnberg, Erlangen, Germany, ⁶CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, ⁷Uniklinik Leipzig, Medizinische Klinik III - Bereich Rheumatologie, Leipzig, Germany, ⁸Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, ⁹Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freibrug, ¹⁰Section Rheumatology, Sozialstiftung Bamberg, Bamberg, Germany, ¹¹Abteilung für Neuroradiologie, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, ¹²Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, ¹³9.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, ¹⁴University of Belgrade Medical School, Belgrade, Serbia, ¹⁵Institute for Experimental Pharmacology, Erlangen, ¹⁶Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: Personalization of RA treatment is not optimal due to lack of predictors. We previously demonstrated in RA patients that central nervous system (CNS) pain…
Abstract Number: 1831 • ACR Convergence 2020
Biomarkers Linked to Anti-IFN-I and Ustekinumab Suggest Distinct Mechanism of Action in Systemic Lupus Erythematosus
Thomas Dörner¹, George Tsokos², Kenneth Kalunian³, Ronald van Vollenhoven⁴, Ashley Orillion⁵, Matteo Cesaroni⁵, Jacqueline Benson⁶, Marc Chevrier⁷, Shawn Rose⁸, Stanley Marciniak⁵, Zhenling Yao⁵, Bhaskar Srivastava⁵, Jessica Schreiter⁵, Frédéric Baribaud⁵, Tatiana Ort⁵, Jarrat Jordan⁵ and Loqmane Seridi⁵, ¹DRFZ and Charité University Hospitals, Berlin, Germany, ²Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, ³University of California San Diego, La Jolla, CA, ⁴Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Research & Development, LLC, South San Francisco, CA, ⁷Janssen Research & Development, LLC, Collegeville, PA, ⁸Janssen Research & Development, LLC, Princeton Junction, NJ
Background/Purpose: Clinical and biological heterogeneity pose a significant hurdle in SLE, making biomarkers that define patient subsets crucial for developing tailored therapies. Interventional SLE trials…
Abstract Number: 0343 • ACR Convergence 2020
Co-expression of DC-STAMP and CX3CR1: Biomarkers for Tissue Resident Osteoclasts in Psoriatic Arthritis
Maria de la Luz Garcia-Hernandez¹, Javier Rangel-Moreno², Ananta Paine³, Benjamin Korman³, Marc Nuzzo⁴, Lihi Eder⁵ and Christopher Ritchlin³, ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY, ³Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁴Department of Medicine, University of Rochester Medical Center, Rochester, ⁵Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) patients often experience joint damage mediated by osteoclasts (OC). Although PsA pathogenesis is poorly understood, the production of the cytokines IL-17,…
Abstract Number: 0731 • ACR Convergence 2020
Comparing S100 Proteins and Cytokine Levels in Tears Based on Uveitis Activity Laterality in Children with JIA-associated Uveitis and Non-JIA-U
Jackeline Rodriguez-Smith¹, Virginia Miraldi Utz², Amy Cassedy¹, Sherry Thornton¹, Grant Schulert³, Alyssa Sproles⁴, Najima Mwase¹, Theresa Hennard¹, Mekibib Altaye², Alexei Grom¹ and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, ³PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati
Background/Purpose: The pathogenesis of pediatric uveitis remains unclear. Studies of biomarkers using aqueous humor (AqH) identified S100 proteins, cytokines, and chemokines as potential biomarkers of…
Abstract Number: 0851 • ACR Convergence 2020
Iberdomide Decreases B Cells and Plasmacytoid Dendritic Cells, Increases Regulatory T Cells and IL-2, and Has Enhanced Clinical Efficacy in Active Systemic Lupus Erythematosus Patients with High Aiolos or the IFN Gene Expression Signature
Peter Lipsky¹, Ronald van Vollenhoven², Thomas Dörner³, Victoria Werth⁴, Joan Merrill⁵, Richard Furie⁶, Milan Petronijevic⁷, Benito Velasco Zamora⁸, Maria Majdan⁹, Fedra Irazoque-Palazuelos¹⁰, Robert Terbrueggen¹¹, Nikolay Delev¹², Michael Weiswasser¹², Shimon Korish¹², Nataliya Agafonova¹², Mark Stern¹³, Sarah Hersey¹³, Ying Ye¹³, Allison Gaudy¹², Zhaohui Liu¹², Shaojun Tang¹³ and Peter Schafer¹², ¹RILITE Foundation, Charlottesville, VA, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³DRFZ and Charité University Hospitals, Berlin, Germany, ⁴University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁷Military Medical Academy, Belgrade, Serbia, ⁸Instituto CER S.A., Buenos Aires, Argentina, ⁹Medical University of Lublin and Samodzielny Publicnzy Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland, ¹⁰Centro de Investigación y Tratamiento Reumatológico S.C, Miguel Hidalgo, Mexico, ¹¹DxTerity Diagnostics Inc, Rancho Dominguez, ¹²Bristol Myers Squibb, Princeton, ¹³Bristol-Myers Squibb, Princeton
Background/Purpose: Iberdomide is a high-affinity cereblon ligand that promotes ubiquitination and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors linked to the genetic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].